# A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

> **NCT05728489** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BI 765250
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05728489
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-27
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728489, "A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05728489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*